SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-056254
Filing Date
2024-05-09
Accepted
2024-05-09 07:05:38
Documents
13
Period of Report
2024-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K amlx-20240509.htm   iXBRL 8-K 45361
2 EX-99.1 amlx-ex99_1.htm EX-99.1 145014
3 GRAPHIC img212534189_0.jpg GRAPHIC 631
  Complete submission text file 0000950170-24-056254.txt   321564

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT amlx-20240509.xsd EX-101.SCH 26845
16 EXTRACTED XBRL INSTANCE DOCUMENT amlx-20240509_htm.xml XML 4531
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

IRS No.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41199 | Film No.: 24928503
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)